Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Early-stage (II/III) melanoma: Risk stratification and treatment decisions

Further development of the clinical case: A medical oncologist’s perspective – Do all patients need adjuvant systemic therapy and how does this influences therapy in advanced setting?

Date

22 Oct 2023

Session

Early-stage (II/III) melanoma: Risk stratification and treatment decisions

Topics

Targeted Therapy;  Immunotherapy;  Survivorship

Tumour Site

Melanoma

Presenters

Mathilde Jalving

Authors

M. Jalving

Author affiliations

  • Medical Oncology Department, UMCG - University Medical Center Groningen, 9700 RB - Groningen/NL

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Presentation of case/condition 

Presenter: Pawel Sobczuk

Session: Early-stage (II/III) melanoma: Risk stratification and treatment decisions

Resources:

Slides

Webcast

Discussion

Presenter: All Speakers

Session: Early-stage (II/III) melanoma: Risk stratification and treatment decisions

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.